EPHA2 and neoplasm: Other EphA2 mAbs include antibody IG25, which promoted EphA2 degradation and reduced the growth of a pancreatic xenograft model, and IG28, which inhibited ephrin-A1 interaction, blocked tumour progression, and resulted in reduced tumour vascularisation when given to mice with orthotopic pancreatic tumours [124].